

Introducing Quantom Biosciences, a Univercells company, with the mission to improve access to essential medicines and autonomy in bioproduction through innovation

Brussels and Nivelles (Belgium), June 17, 2021

Univercells S.A. introduces its latest affiliate, Quantom Biosciences S.A., a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through innovation. Quantom Biosciences develops clinically validated technology platforms that will address some of the biggest production challenges in vaccines and therapeutics, supporting decentralized production. R&D facilities are strategically located in Belgium, in the heart of Europe.

With its open, fully integrated and affordable RNA platform, Quantom Biosciences provides research organizations, CDMO's and biopharma companies greater access and autonomy to RNA production that would otherwise be out of their reach. Partners benefit from capabilities, know-how and secured access to critical components to produce any desired RNA product without being tied to a drug developer. The technology is designed to scale seamlessly from small-scale (e.g., pre-clinical batches) to mass production to meet capacity needs throughout – from lab to launch and beyond.

Quantom Biosciences is a team of scientists, engineers and clinicians bringing radical innovation to vaccines and therapeutics production, led by José Castillo co-founder of Univercells. A serial entrepreneur, José previously co-founded Artelis, where he invented the iCellis bioreactor, which became industry standard for cell and gene therapy. Artelis was acquired by ATMI in 2010, later by Danaher (now Pall) in 2014. In parallel to Univercells, José also co-founded MaSTherCell in 2011, a leading CDMO in cell therapy (now Catalent). He is known as one of the best bioprocess innovators in the world.

José Castillo, CEO of Quantom Biosciences commented: “The COVID-19 pandemic has underlined the desperate need for technological innovation in manufacturing. By lowering the barriers, we allow our partners that have previously not considered exploring RNA-based vaccines and therapeutics, to enter the market and make independent, informed decisions about their product development and strategy. This is a very exciting moment, and we look forward to achieving our first milestone in the coming months.”

Hugues Bultot, CEO of Univercells added: “We are delighted to welcome Quantom Biosciences into the Group. This new affiliate is Univercells' innovation driver, building the future of biomanufacturing through technologies, and will contribute to the Group vision of making biologics available to all.”

●●● About Univercells ●●●

Univercells is a global life sciences company that makes biologics available to all. Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability. Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.

Univercells is headquartered in Gosselies (Belgium) and benefits from the support of regional and national investors, as well as international investors, such as the Bill & Melinda Gates Foundation, EIB, Global Health Investment Fund, among others active in the health and vaccine industry.

www.univercells.com

●●● About Quantoom Biosciences ●●●

Quantoom Biosciences is a biotech with the mission to deliver greater access and autonomy through innovation in bioproduction that will address some of the biggest production challenges in vaccines and therapeutics. As a Univercells company, Quantoom Biosciences provides open, fully integrated, affordable and (pre)clinically proven platforms to make biologics available for all. Our facilities are strategically located in Belgium, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

www.quantoom.com

●●● Disclosure Statement ●●●

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Univercells S.A.
Alexandra Deschner
IR & International Media Relations
investors@univercells.com
+32.490.58.35.23

Univercells S.A.
Cécile Hisette
Belgian Media Relations
info@cecili-z.be
+32.473.36.14.11

Quantoom Biosciences S.A.
José Castillo
Chief Executive Officer
press@quantoom.com